American Century Companies Inc. reduced its stake in Becton Dickinson and Co (NYSE:BDX) by 0.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,170,049 shares of the medical instruments supplier’s stock after selling 5,362 shares during the period. American Century Companies Inc.’s holdings in Becton Dickinson and were worth $250,461,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Patten Group Inc. increased its holdings in Becton Dickinson and by 181.4% in the fourth quarter. Patten Group Inc. now owns 5,777 shares of the medical instruments supplier’s stock valued at $1,237,000 after buying an additional 3,724 shares during the last quarter. Raymond James Trust N.A. increased its holdings in Becton Dickinson and by 8.6% in the fourth quarter. Raymond James Trust N.A. now owns 6,411 shares of the medical instruments supplier’s stock valued at $1,372,000 after buying an additional 505 shares during the last quarter. Dowling & Yahnke LLC increased its holdings in Becton Dickinson and by 3.4% in the fourth quarter. Dowling & Yahnke LLC now owns 8,108 shares of the medical instruments supplier’s stock valued at $1,736,000 after buying an additional 270 shares during the last quarter. Harbour Investment Management LLC purchased a new position in Becton Dickinson and in the fourth quarter valued at $2,375,000. Finally, Meeder Asset Management Inc. purchased a new position in Becton Dickinson and in the fourth quarter valued at $160,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Several equities analysts recently commented on BDX shares. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 target price on the stock in a report on Wednesday, January 3rd. Deutsche Bank set a $260.00 target price on Becton Dickinson and and gave the company a “buy” rating in a report on Friday, December 29th. Argus increased their target price on Becton Dickinson and to $235.00 and gave the company a “buy” rating in a report on Thursday, December 14th. They noted that the move was a valuation call. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a report on Friday, November 3rd. Finally, Bank of America reissued a “buy” rating and issued a $260.00 target price on shares of Becton Dickinson and in a report on Friday, January 19th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $237.27.

Becton Dickinson and Co (BDX) opened at $221.92 on Thursday. The stock has a market capitalization of $50,910.00, a PE ratio of 169.40, a price-to-earnings-growth ratio of 1.60 and a beta of 1.12. Becton Dickinson and Co has a twelve month low of $175.66 and a twelve month high of $248.39. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.41 by $0.07. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.33 earnings per share. sell-side analysts forecast that Becton Dickinson and Co will post 10.92 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.35%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s payout ratio is 229.01%.

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2018/02/08/american-century-companies-inc-has-250-46-million-stake-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.